title: [Effects of combined therapy with domestic inhalational anti-asthmatic drugs on oxidant status of patients with bronchial asthma].
abstract: OBJECTIVE
  To compare effectiveness of two combinations of domestic drugs in the form of dry powder for inhalation-biasten containing budesonide plus salbutamol hemisuccinate and benacort (budesonide) plus salben (salbutamol) in correction of disorders of the blood oxidant-antioxidant system (OAS) in patients with moderate bronchial asthma (BA).
  
  
  METHODS
  A total of 46 patients with uncontrollable BA of moderate severity (16 males and 30 females) entered an open trial where they were randomized into two groups. Group 1 (n=25) inhaled biasten (2 inhalations 2 times a day), group 2 (n=21) received equivalent doses of benacort and salben for 12 weeks. The following parameters were assessed: a clinical response, peakflowmetry, flow-volume curve, daily need in beta2-agonists, OAS by intensity of methemoglobin (MET) spectra, free radicals (FR), catalase, ceruloplasmin, transferrin, superoxidedismutase (SOD).
  
  
  RESULTS
  Biasten treatment for 12 weeks brought about a good control over BA symptoms in 72% patients, satisfactory--in 24%, no control--in one patient. In combined therapy with benacort and salben the respective percentage was 71.4 and 19.1, failure--in 2 patients. A clinical response in both groups differed insignificantly. The responders showed significant correction of OAS unbalance (but not of OAS erythrocytes), reduction of MET and FR concentrations, elevation of SOD and catalase. Anti-oxidant properties of blood plasm did not change significantly in response to the studied drugs administration.
  
  
  CONCLUSIONS
  Both biasten and benacort in combination with salben provide BA control, reduce severity of free radical oxidation disorders.
authors.forename: A F
authors.initials: AF
authors.lastname: Kolpakova
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005609:Free Radicals / Q000097:blood; D006801:Humans; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D008706:Methemoglobin / Q000032:analysis; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D018384:Oxidative Stress / Q000187:drug effects*; D011208:Powders; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000975:Antioxidants; D004338:Drug Combinations; D005609:Free Radicals; D008054:Lipid Peroxides; D011208:Powders; D019819:Budesonide; D008706:Methemoglobin; D000420:Albuterol